Can mast cell activation syndrome be chronic, and is obtaining a true baseline serum tryptase difficult in a young‑to‑middle‑aged adult female with 1–2 years of recurrent flushing, urticaria, abdominal cramping, tachycardia and wheezing?

MCAS Can Present with Chronic Symptoms, But True MCAS Requires Episodic Flares—and Obtaining a True Baseline Tryptase Is Feasible Even After 1–2 Years

MCAS is fundamentally an episodic disorder, not a chronic one; persistent daily symptoms without discrete flares argue against the diagnosis and should redirect you toward functional disorders, POTS, or other conditions. 1 However, patients may experience mild inter-episode symptoms, and establishing a baseline tryptase remains straightforward: draw it during any asymptomatic or minimally symptomatic period, even years into the illness. 1, 2

---

Core Diagnostic Framework: MCAS Is Episodic, Not Chronic

• MCAS requires recurrent acute episodes affecting ≥2 organ systems simultaneously—cardiovascular (tachycardia, hypotension), dermatologic (urticaria, flushing), respiratory (wheezing), and gastrointestinal (cramping, diarrhea). 1, 2

• Persistent, chronic symptoms between episodes are a red flag against MCAS. 1 The American Academy of Allergy, Asthma, and Immunology explicitly states that continuous symptoms should direct you to alternative diagnoses such as functional GI disorders, POTS, or systemic mastocytosis. 1

• Mild residual symptoms between flares may occur (e.g., low-grade nausea, fatigue), but the hallmark is discrete, severe exacerbations. 1 If your patient has had 1–2 years of unremitting daily symptoms without clear episodic worsening, MCAS is unlikely. 1

---

Obtaining Baseline Tryptase: Straightforward Even After Years of Symptoms

When and How to Draw Baseline Tryptase

• Baseline tryptase is measured during an asymptomatic or minimally symptomatic period—it does not require the patient to be symptom-free for months. 1, 2 Even after 1–2 years of illness, you can obtain a valid baseline during any inter-episode window. 1, 2

• The baseline serves as the individual's reference point for calculating the diagnostic rise during acute episodes. 1, 2, 3

Diagnostic Tryptase Rise During Episodes

• Acute tryptase must be drawn 1–4 hours after symptom onset during a discrete flare. 1, 2

• The diagnostic threshold is ≥20% above baseline plus an absolute increase of ≥2 ng/mL, documented on at least two separate episodes. 1, 2, 3, 4 This "20% + 2" formula was validated specifically to account for varying baseline levels (low, normal, or elevated) and remains the gold standard. 3, 4

Common Pitfall: Chronically Elevated Baseline Tryptase

• A persistently elevated baseline tryptase (>20 ng/mL) without episodic symptoms does not satisfy MCAS criteria. 1, 2 This pattern suggests systemic mastocytosis or hereditary α-tryptasemia, both of which require further workup (bone marrow biopsy, TPSAB1 gene testing). 1, 2

---

Alternative Mediators When Tryptase Is Difficult to Obtain

If your patient cannot reach a lab during acute episodes, 24-hour urine collections for mast cell mediator metabolites provide complementary evidence: 1, 2, 5, 6

• Urinary leukotriene E4 (LTE4): peaks 0–6 hours post-episode; an acute/baseline ratio ≥1.3 supports MCAS. 2, 6

• Urinary 11β-prostaglandin F2α: peaks 0–3 hours; ratio ≥1.3 correlates with anaphylactic severity and guides aspirin therapy. 2, 6

• Urinary N-methylhistamine: less sensitive than the above but can be used; ratio ≥1.3 is supportive. 2, 6

Key advantage: Urine collections can be done at home and are non-invasive. 5, 7

---

Completing the Diagnostic Triad

Beyond mediator elevation, two additional criteria are mandatory: 1, 2

1. Clinical response to mast cell–targeted therapy (H1/H2 antihistamines at 2–4× standard doses, oral cromolyn, leukotriene antagonists). 1, 2 Response should be assessed over 2–6 weeks. 2

2. Exclusion of secondary causes (IgE-mediated allergy, NSAID hypersensitivity, drug reactions, infections). 2, 7

---

Differential Diagnosis for Chronic Symptoms in This Patient

In a young-to-middle-aged woman with 1–2 years of flushing, urticaria, abdominal cramping, tachycardia, and wheezing:

• If symptoms are persistent rather than episodic, consider:

  • Functional GI disorders (IBS, functional dyspepsia). 1
  • POTS (can cause chronic nausea, tachycardia, abdominal pain independent of MCAS). 1
  • Chronic urticaria or asthma (single-organ involvement). 1

• If symptoms are episodic with clear flares, proceed with MCAS workup as outlined above. 1, 2

• Hormonal triggers (menstrual cycle, pregnancy) are recognized MCAS precipitants in some patients, but diagnosis still requires documented mediator elevation during episodes. 8

---

Practical Algorithm for This Patient

1. Clarify symptom pattern: Are there discrete, severe episodes with symptom-free or near-symptom-free intervals? 1

   • Yes → Proceed to step 2.
   • No (chronic, unremitting symptoms) → Pursue alternative diagnoses (POTS, functional GI, chronic urticaria). 1

2. Obtain baseline tryptase during the next asymptomatic or minimally symptomatic window. 1, 2

3. Instruct the patient to present for acute tryptase draw within 1–4 hours of the next severe episode. 1, 2 If this is logistically impossible, provide 24-hour urine collection kits for LTE4, 11β-PGF2α, and N-methylhistamine to be collected during and between episodes. 2, 5, 7, 6

4. Calculate the tryptase rise using the 20% + 2 formula; for urine mediators, look for acute/baseline ratios ≥1.3. 1, 2, 3, 6, 4

5. Initiate empiric mast cell–targeted therapy (H1 antihistamine at 2–4× dose + H2 antagonist) and assess response over 2–6 weeks. 2

6. If all three criteria are met (episodic symptoms, mediator rise on ≥2 occasions, therapeutic response), diagnose MCAS and refer to an allergy/mast cell specialist for subtyping (KIT D816V testing, bone marrow biopsy if baseline tryptase >20 ng/mL). 1, 2, 7

---

Key Pitfalls to Avoid

• Over-diagnosis: Do not label chronic, non-episodic symptoms as MCAS without documented mediator elevation. 1, 2

• Ignoring the episodic requirement: MCAS is not a diagnosis of exclusion for unexplained multisystem complaints. 1

• Misinterpreting elevated baseline tryptase: A high baseline without episodic rises suggests systemic mastocytosis or hereditary α-tryptasemia, not MCAS. 1, 2